Dr. Whitworth on Treating Breast Cancer With Chemo

Pat W. Whitworth, MD
Published: Tuesday, Apr 17, 2012

Pat W. Whitworth, MD, Associate Clinical Professor of Surgery, Vanderbilt University Medical Center, explains there is a strong historical connection between treating patients with chemotherapy and the risk of recurrence for patients with breast cancer.

Traditionally providing chemotherapy to high-risk patients was tied to concerns for the patient. The higher the concern the more likely the patient was to receive chemotherapy. Early on there was not an accurate way to target chemotherapy sensitive patients, which is why lymph node status was used as an indicator.

There was a paradigm shift in 2006 when the B20 chemotherapy benefit study discovered that a 21-gene assay could determine a patient’s sensitivity to chemotherapy. This helped change the way that oncologists thought about risk and chemotherapy.

Whitworth notes that it is difficult to translate a change in understanding into a change in practice, especially given the strong emotional connection between risks and chemotherapy.

Pat W. Whitworth, MD, Associate Clinical Professor of Surgery, Vanderbilt University Medical Center, explains there is a strong historical connection between treating patients with chemotherapy and the risk of recurrence for patients with breast cancer.

Traditionally providing chemotherapy to high-risk patients was tied to concerns for the patient. The higher the concern the more likely the patient was to receive chemotherapy. Early on there was not an accurate way to target chemotherapy sensitive patients, which is why lymph node status was used as an indicator.

There was a paradigm shift in 2006 when the B20 chemotherapy benefit study discovered that a 21-gene assay could determine a patient’s sensitivity to chemotherapy. This helped change the way that oncologists thought about risk and chemotherapy.

Whitworth notes that it is difficult to translate a change in understanding into a change in practice, especially given the strong emotional connection between risks and chemotherapy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x